TickerFacts.

Impact Biomedical Inc. (IBO): Shareholders' Equity

Annual figures by period end, from SEC filings.

$12.61M
As of 2025-12-31
$10.77M
As of 2026-06-30
-24.7%
3-year compound annual growth
$29.56M2022-12-31: $29.56M2023-12-31: $25.22M2024-12-31: $4.26M2025-12-31: $12.61M$12.61M
2022-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$12.61M+196.1%2026-03-11, Balance as of period end
2024-12-31$4.26M-83.1%2026-03-11, Balance as of period end
2023-12-31$25.22M-14.7%2025-03-28, Balance as of period end
2022-12-31$29.56Mn/a2024-02-20, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Impact Biomedical Inc. (IBO)2025-12-31$12.61M+196.1%
Lyell Immunopharma, Inc. (LYEL)2025-12-31$248.20M-35.2%
Talphera, Inc. (TLPH)2025-12-31$17.04M+112.9%
Neonc Technologies Holdings, Inc. (NTHI)2025-12-31-$17.51Mn/m
Altimmune, Inc. (ALT)2025-12-31$224.89M+82.1%
Jupiter Neurosciences, Inc. (JUNS)2025-12-31-$1.83Mn/m
Skinvisible, Inc. (SKVI)2025-12-31-$10.26Mn/m
Lunai Bioworks Inc. (LNAI)2026-06-30-$9.02Mn/m
HCW Biologics Inc. (HCWB)2025-12-31$2.76Mn/m

Compare IBO, LYEL, TLPH, NTHI side by side · Screen every company in Pharmaceutical Preparations ↗